I am not sure how to feel about this. The drug costs $27k a year.<p>"In studies reviewed by the FDA, Leqembi appeared to slow declines in memory and thinking by about 27% after 18 months of treatment. It also dramatically reduced the sticky beta-amyloid plaques that tend to build up in the brains of people with Alzheimer's."<p>There are life-threatening side effects. Although, the diseases is awful itself and I would probably choose death.<p>However, this drug had an accelerated approval. This makes me a bit uneasy. It signals to drug companies that they can pick any terminal illness, develop a drug for it, show minimal efficacy, and get quick approval even if the side effects are deadly. In the end they profit.<p>Will this lead to more drugs? Faster scientific research? Or higher profits for the drug companies?
> In January, the drug received what's known as accelerated approval from the FDA, based on its ability to remove the substance beta-amyloid from the brains of people in the early stages of Alzheimer's.<p>Whenever beta-amyloids come up, I recall that they seem to be quite divisive. Can someone explain to me what the debate is about? The FDA appears to believe that they are a cause of Alzheimer’s based on this drug’s approval